302 related articles for article (PubMed ID: 28521199)
1. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
[TBL] [Abstract][Full Text] [Related]
2. Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.
Oviedo-Joekes E; Palis H; Guh D; Marsh DC; MacDonald S; Harrison S; Brissette S; Anis AH; Schechter MT
J Addict Med; 2019; 13(5):354-361. PubMed ID: 30747750
[TBL] [Abstract][Full Text] [Related]
3. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
[TBL] [Abstract][Full Text] [Related]
5. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.
Oviedo-Joekes E; Marsh DC; Guh D; Brissette S; Schechter MT
J Opioid Manag; 2011; 7(5):371-6. PubMed ID: 22165036
[TBL] [Abstract][Full Text] [Related]
6. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
[TBL] [Abstract][Full Text] [Related]
7. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Nosyk B; Krausz M; Anis A; Schechter MT
J Subst Abuse Treat; 2010 Jun; 38(4):408-11. PubMed ID: 20359843
[TBL] [Abstract][Full Text] [Related]
8. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
[TBL] [Abstract][Full Text] [Related]
9. Diacetylmorphine versus methadone for the treatment of opioid addiction.
Oviedo-Joekes E; Brissette S; Marsh DC; Lauzon P; Guh D; Anis A; Schechter MT
N Engl J Med; 2009 Aug; 361(8):777-86. PubMed ID: 19692689
[TBL] [Abstract][Full Text] [Related]
10. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
Marchand KI; Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Schechter MT
BMC Health Serv Res; 2011 Jul; 11():174. PubMed ID: 21791093
[TBL] [Abstract][Full Text] [Related]
11. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.
Oviedo-Joekes E; Marchand K; Lock K; MacDonald S; Guh D; Schechter MT
Subst Abuse Treat Prev Policy; 2015 Jan; 10():3. PubMed ID: 25619263
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
[TBL] [Abstract][Full Text] [Related]
13. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).
Allen ST; Schneider KE; Rouhani S; White RH; Morris M; Owczarzak J; Sherman SG
Ann Med; 2023 Dec; 55(1):2196435. PubMed ID: 37078710
[TBL] [Abstract][Full Text] [Related]
14. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.
Maghsoudi N; Bowles J; Werb D
Can J Public Health; 2020 Aug; 111(4):606-609. PubMed ID: 32221867
[TBL] [Abstract][Full Text] [Related]
15. Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.
Oviedo-Joekes E; Sordo L; Guh D; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
Addict Behav; 2015 Feb; 41():81-6. PubMed ID: 25452049
[TBL] [Abstract][Full Text] [Related]
16. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.
Oviedo-Joekes E; Guh D; Marchand K; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
Subst Abuse Treat Prev Policy; 2014 Jun; 9():23. PubMed ID: 24908387
[TBL] [Abstract][Full Text] [Related]
17. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
Fairbairn N; Ross J; Trew M; Meador K; Turnbull J; MacDonald S; Oviedo-Joekes E; Le Foll B; Goyer MÈ; Perreault M; Sutherland C
CMAJ; 2019 Sep; 191(38):E1049-E1056. PubMed ID: 31548191
[No Abstract] [Full Text] [Related]
18. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.
Palis H; Guh D; MacDonald S; Harrison S; Brissette S; Marsh DC; Schechter MT; Oviedo-Joekes E
Drug Alcohol Depend; 2021 Jan; 218():108333. PubMed ID: 33268225
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
